Celcuity (NASDAQ:CELC) Director David Dalvey Sells 20,000 Shares of Stock

Celcuity, Inc. (NASDAQ:CELC) Director David Dalvey sold 20,000 shares of the business’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total value of $2,400,600.00. Following the sale, the director directly owned 90,000 shares of the company’s stock, valued at $10,802,700. This represents a 18.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Celcuity Stock Down 2.1%

NASDAQ CELC opened at $112.12 on Friday. Celcuity, Inc. has a 52 week low of $7.57 and a 52 week high of $120.32. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74. The company has a market capitalization of $5.19 billion, a P/E ratio of -30.55 and a beta of 0.25. The stock’s 50-day moving average price is $104.00 and its 200-day moving average price is $71.07.

Celcuity (NASDAQ:CELC) last released its earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.13. On average, equities research analysts predict that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

CELC has been the subject of a number of analyst reports. Wolfe Research initiated coverage on Celcuity in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $110.00 price target for the company. HC Wainwright reiterated a “neutral” rating and set a $94.00 target price (up previously from $77.00) on shares of Celcuity in a research report on Monday, November 17th. Stifel Nicolaus lifted their target price on Celcuity from $68.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Wells Fargo & Company assumed coverage on Celcuity in a research note on Friday, December 12th. They issued an “overweight” rating and a $126.00 price target for the company. Finally, Craig Hallum increased their price objective on shares of Celcuity from $96.00 to $108.00 and gave the company a “buy” rating in a report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $105.25.

Hedge Funds Weigh In On Celcuity

Institutional investors and hedge funds have recently modified their holdings of the stock. Apis Capital Advisors LLC purchased a new stake in Celcuity during the 3rd quarter valued at $38,334,000. UBS Group AG raised its stake in shares of Celcuity by 910.1% in the third quarter. UBS Group AG now owns 854,483 shares of the company’s stock valued at $42,211,000 after acquiring an additional 769,891 shares during the period. Deerfield Management Company L.P. bought a new stake in shares of Celcuity in the 3rd quarter worth about $36,236,000. Alliancebernstein L.P. boosted its stake in shares of Celcuity by 2,208.6% during the 3rd quarter. Alliancebernstein L.P. now owns 652,649 shares of the company’s stock worth $32,241,000 after purchasing an additional 624,379 shares during the period. Finally, Soleus Capital Management L.P. boosted its stake in shares of Celcuity by 17.0% during the 2nd quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after purchasing an additional 437,696 shares during the period. Hedge funds and other institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.